Invariant natural killer T (iNKT) cells represent a unique lymphocyte subset that bridges innate and adaptive immunity. Their development originates in the thymus from double‐positive precursor cells, ...

Cancer-killing T cells have been programmed to have two levels of specificity. First, the T cells have been equipped with a receptor sensitive to a protein that is found only in central nervous system ...

Why do immune cells that are supposed to eliminate viruses suddenly turn against our own body? There are instances where killer T cells—which are meant to precisely remove virus-infected ...

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors. Now ...

“CAR-T cells are very potent cells. However, the most surprising finding in our work is that these potent cells are strongly inhibited in tumor models that recapitulate the complexity of the tumor ...

“The dual function of MiTEs enables them to attack the tumor from multiple immune angles at once,” explains von Locquenghien.

Casitas B-lineage lymphoma-b (CBLB) is an E3 ubiquitin–protein ligase that functions as an intracellular checkpoint and ...

In mice, MiTE treatment shrank tumors and reshaped the immune landscape; in human kidney cancer samples, it sparked strong immune activation. “The future of immunotherapy lies in combining safety with ...

Though many research institutions have a common goal of finding new ways to treat or even cure cancer, the pathways to that goal are often diverse. One new study coming out of a La Jolla lab — in ...

When the immune system overreacts and starts attacking the body, the only option may be to shut the entire system down and risk developing infections or cancer. But now, scientists at UC San Francisco ...